// App-Quantinova.ai

603 : Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Researchers

Presenter

  • Saranya Chumsri

Principal Investigators

  • Jeff Sperinde

  • Heshan Liu

  • Joseph Gligorov

  • Jean-Philippe Spano

  • Alvaro Moreno-Aspitia

  • Sarah A. McLaughlin

  • John William Winslow

  • Christos J. Petropoulos

  • Ahmed Chenna

  • Michael Patrick Bates

  • Jodi Marie Weidler

  • Yolanda Lie

  • Weidong Huang

  • Edith A. Perez

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • Monogram Biosciences, Inc., South San Francisco, CA

  • Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

  • APHP Tenon, Med Oncology Dept, Paris, France

  • Pitie-Salpetriere University Hospital, Paris, France

  • Mayo Clinic, Jacksonville, FL

  • Monogram Biosciences Inc, El Granada, CA

  • Monogram Biosciences, Inc., South San Francisco, CA

  • Home, Sunnyvale, CA

  • Cepheid Inc, Sunnyvale, CA

  • Monogram Biosciences Inc/LabCorp, Pleasanton, CA

Locations

  • United States

  • France

Companies

  • Monogram Biosciences

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved